Drug Trial Radar · NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Mar 12, 2020
Primary completion
Sep 30, 2026
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Turning Point Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Conditions
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
- Lymphoma
- Primary CNS Tumors
Interventions
Oral repotrectinib (TPX-0005)Drug
Oral repotrectinib (TPX-0005)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs) (Phase 1)Time frame: Within 28 days of the first repotrectinib dose
- Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Within 28 days of the last patient dosed in escalation
- Overall Response Rate (ORR) (Phase 2)Time frame: Two to three years after first dose of repotrectinib
Locations
68 sites in 11 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
University of California at Los Angeles
Los Angeles, California · Recruiting
Children's Hospital Colorado - Anschutz Medical Campus
Aurora, Colorado · Recruiting
Local Institution - 2105
Orlando, Florida · Completed
Local Institution - 2120
Orlando, Florida · Completed
Children's Healthcare of Atlanta - Egleston Hospital
Atlanta, Georgia · Recruiting
Maine Medical Center
Scarborough, Maine · Recruiting
Dana Farber Cancer Institute.
Boston, Massachusetts · Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri · Recruiting
Local Institution - 2110
New Brunswick, New Jersey · Completed
Local Institution - 2102
New York, New York · Completed
Levine Children's Hospital- Pediatric Neuro-Oncology
Charlotte, North Carolina · Recruiting
Local Institution - 2112
Cleveland, Ohio · Completed
Local Institution - 2114
Hershey, Pennsylvania · Completed
Children's Hospital of Philadelphia-Center for Childhood Cancer Research
Philadelphia, Pennsylvania · Recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center
Dallas, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Local Institution - 2104
Houston, Texas · Completed
Children's Hospital of Richmond at VCU
Richmond, Virginia · Withdrawn
Local Institution - 6104
Randwick, New South Wales, Australia · Recruiting
Local Institution - 6103
Westmead, New South Wales, Australia · Completed
Children's Health Queensland Hospital and Health Service
South Brisbane, Queensland, Australia · Recruiting
Perth Childrens Hospital
Nedlands, Western Australia, Australia · Recruiting
University Of Calgary
Calgary, Alberta, Canada · Recruiting
Stollery Children'S Hospital
Edmonton, Alberta, Canada · Recruiting
Children'S Hospital Of Eastern Ontario
Ottawa, Ontario, Canada · Recruiting
St Justine Hospital
Montreal, Quebec, Canada · Recruiting
Rigshospitalet - Glostrup
Copenhagen, Denmark · Recruiting
Centre Hospitalier Universitaire D'Angers
Angers, France · Recruiting
Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, France · Recruiting
Institut d Hematologie et d Oncologie Pediatriques
Lyon, France · Recruiting
Hôpitaux Universitaires de Marseille Timone
Marseille, France · Recruiting
Local Institution - 6110
Marseille, France · Not yet recruiting
Local Institution - 6112
Nantes, France · Not yet recruiting
Local Institution - 6109
Paris, France · Not yet recruiting
Institut Gustave-Roussy
Villejuif, France · Recruiting
Local Institution - 6108
Villejuif, France · Not yet recruiting
Local Institution - 6111
Lyon, Rhone, France · Not yet recruiting
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy · Recruiting
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.